Hyloris Pharmaceuticals S.A.
HYL.BR · BRU
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | €0 | €0 | €0 | €0 |
| % Growth | 0% | -38.2% | 0% | – |
| Cost of Goods Sold | €0 | €0 | €0 | €0 |
| Gross Profit | €0 | €0 | €0 | €0 |
| % Margin | 96.2% | 96.2% | 97.8% | 97.8% |
| R&D Expenses | €0 | €0 | €0 | €0 |
| G&A Expenses | €0 | €0 | €0 | €0 |
| SG&A Expenses | €0 | €0 | €0 | €0 |
| Sales & Mktg Exp. | €0 | €0 | €0 | €0 |
| Other Operating Expenses | -€0 | -€0 | €0 | €0 |
| Operating Expenses | €0 | €0 | €0 | €0 |
| Operating Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -105.8% | -105.8% | -58.4% | -58.4% |
| Other Income/Exp. Net | -€0 | -€0 | €0 | €0 |
| Pre-Tax Income | -€0 | -€0 | -€0 | -€0 |
| Tax Expense | €0 | €0 | €0 | €0 |
| Net Income | -€0 | -€0 | -€0 | -€0 |
| % Margin | -106.5% | -106.5% | -52.9% | -52.9% |
| EPS | -0.065 | -0.065 | -0.049 | -0.049 |
| % Growth | 0% | -32.7% | 0% | – |
| EPS Diluted | -0.065 | -0.065 | -0.049 | -0.049 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | €0 | €0 | €0 | €0 |
| Interest Expense | €0 | €0 | €0 | €0 |
| Depreciation & Amortization | €0 | €0 | €0 | €0 |
| EBITDA | -€0 | -€0 | -€0 | -€0 |
| % Margin | -96.4% | -96.4% | -22.6% | -22.6% |